CVSP-AIE is a highly sophisticated integration of three cutting-edge AI-powered models, each tailored for a distinct phase of the molecular docking pipeline. The platform harmonizes rapid docking with pinpoint precision and an advanced affinity scoring system, orchestrating a seamless balance between computational efficiency and predictive accuracy. This meticulous blend of speed and rigor addresses a long-standing bottleneck in virtual screening workflows: harnessing AI’s computational prowess without sacrificing the quality of predictions.

The first AI component, KarmaDock, is engineered to perform ultra-fast docking by directly refining atomic coordinates of molecules within the protein binding site. Unlike traditional docking methods that rely heavily on heuristic search algorithms and exhaustive conformational sampling, KarmaDock leverages a streamlined, data-driven approach. By rapidly adjusting atomic positions in three-dimensional space, it expedites the initial pose prediction phase, cutting down processing time dramatically without compromising the structural plausibility of the docked complex.

Following the rapid pose generation stage, the platform invokes CarsiDock, an AI model specializing in precision docking accuracy. Instead of depending solely on scoring functions to discern the best pose, CarsiDock predicts protein–ligand interatomic distances and reconstructs the binding conformations with remarkable fidelity. This approach circumvents common pitfalls of docking algorithms that struggle with flexible binding regions or subtle steric clashes, ensuring that the resultant poses reflect realistic biochemical interactions.

Complementing these docking innovations is RTMScore, an affinity prediction engine that pushes proteochemometric modeling to new heights. RTMScore learns from detailed residue–atom distance distributions within the complex, capturing nuanced intermolecular forces that dictate binding strength. This contrasts starkly with conventional scoring functions that often simplify interaction energy landscapes into aggregated terms, risking loss of critical molecular context. RTMScore’s fine-grained analytical capacity translates to more reliable identification of tightly binding ligands, elevating the hit-to-lead conversion success rate.

Together, these AI modules form a hierarchical workflow within CVSP-AIE, strategically modulating screening throughput and accuracy demands. Initial docking with KarmaDock screens large libraries quickly, funneling top candidates through the more computationally intensive but precise evaluation of CarsiDock and RTMScore. This tiered strategy mirrors human expert intuition: broad preliminary filtering followed by focused scrutiny, yet now performed by an intelligent, autonomous system at unprecedented scale.

Accessibility sets CVSP-AIE apart from many advanced in silico tools. Available as an online web-server via a user-friendly interface (https://cadd.zju.edu.cn/cvsp/), it democratizes access to advanced AI-driven VS technologies. Researchers simply upload a protein target structure alongside a known binder to define the binding pocket, jumpstarting the automated drug screening pipeline. This intuitive yet powerful capability lowers the barrier to entry for scientists, from academic labs to industry R&D teams, accelerating translational research timelines.

The platform’s workflow unfolds in three core phases, starting with comprehensive preprocessing. Here, protein structures undergo meticulous repair to address missing atoms or residues, while molecular inputs are standardized to ensure compatibility with downstream AI models. These steps are crucial to maintain the integrity and reproducibility of the docking process, mitigating errors that can cascade in large-scale virtual screening campaigns.

Following preprocessing, the heart of CVSP-AIE takes center stage: binding pose generation and affinity prediction. By deploying KarmaDock, CarsiDock, and RTMScore in sequence, the system iteratively refines candidate molecules’ spatial orientations and evaluates their binding potentials. This automated yet sophisticated processing pipeline runs efficiently at scale, requiring only 30 to 45 minutes to hierarchically screen 100,000 compounds — a remarkable performance benchmark that empowers rapid hit identification against diverse druggable targets.

Postprocessing completes the virtual screening cycle by calculating protein–ligand interaction profiles and generating visually interactive chemical space analyses. This integrative presentation enables researchers to explore structure-activity relationships and intermolecular contacts in an intuitive manner. The rich output not only prioritizes compounds by predicted affinities but also offers insights into binding mode diversity, guiding rational lead optimization strategies.

Beyond web accessibility, CVSP-AIE equips users with a robust local software package and a versatile command-line module, facilitating unrestricted large-scale screening on high-performance computing clusters. This on-premise deployment caters to projects requiring extensive compound libraries or privacy-sensitive datasets, reflecting the platform’s adaptability to varied scientific contexts.

In an era defined by computational breakthroughs powered by AI, CVSP-AIE exemplifies the fusion of machine intelligence and chemical biology to accelerate drug discovery pipelines fundamentally. By addressing the dual imperatives of screening speed and predictive robustness, it propels researchers toward unlocking new therapies with unprecedented efficiency. The platform’s emergence signals a paradigm shift where intelligent automation becomes the norm, transcending traditional computational limitations.

The team behind CVSP-AIE envisions broad future applications, extending beyond small-molecule drug discovery to encompass biologics and chemical probes, emphasizing modular AI enhancements to accommodate evolving structural biology challenges. Integration with complementary experimental validation workflows also promises to elevate translational success, transforming theoretical predictions into tangible therapeutic advances.

As CVSP-AIE gains traction within the scientific community, its open accessibility and hierarchical AI framework are poised to inspire further innovation in computational drug discovery. This breakthrough demonstrably bridges the gap between cutting-edge AI methodologies and real-world pipeline demands, fostering an era wherein rapid, accurate, and accessible virtual screening reshapes the quest for next-generation medicines.

Subject of Research: Structure-based virtual screening in drug discovery enhanced by artificial intelligence technologies.

Article Title: Facilitating structure-based drug discovery with an artificial intelligence-driven virtual screening platform.

Article References:
Gu, S., Zhang, X., Xiao, M. et al. Facilitating structure-based drug discovery with an artificial intelligence-driven virtual screening platform. Nat Protoc (2026). https://doi.org/10.1038/s41596-026-01389-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-026-01389-z

At the heart of this revolution is the ability of large language models to process and interpret extraordinarily complex biological and chemical data with near-human cognitive fluency. Unlike traditional computational methods that rely heavily on rule-based algorithms or limited datasets, LLMs leverage vast corpora of biomedical literature, molecular databases, and clinical records. This capability empowers them to identify novel drug candidates that might have otherwise gone unnoticed amid the vastness of chemical and protein interaction spaces. Dr. Anqi Lin, a key author of the study, emphasizes that these models deliver a “quantum leap” in pharmaceutical innovation by uncovering hidden correlations and generating hypotheses at unprecedented speeds.

One of the most promising applications of LLMs lies in the initial stages of drug discovery—target identification and drug screening. Utilizing specialized protein-focused language models such as GPCR LLMs and ProtChat, researchers now integrate 3D structural data of proteins with interaction predictions, vastly improving the reliability of identifying viable drug targets. These advanced models effectively forecast drug-target interactions, enabling high-throughput virtual screening of compounds that could modulate specific biological pathways. This approach not only expedites the identification process but significantly reduces the financial and temporal burdens conventionally associated with experimental screening.

Beyond target identification, LLMs are redefining drug molecular design and optimization. Models like 3DSMILES-GPT and FragGPT offer a leap forward in generating and refining molecular structures with optimized pharmacological properties. These systems employ sophisticated natural language processing techniques to encode molecular graphs and chemical syntax, allowing them to propose novel molecules with enhanced efficacy, stability, and bioavailability. In parallel, platforms such as DrugAssist utilize these models to fine-tune molecular candidates, optimizing them iteratively to improve therapeutic performance while minimizing adverse effects.

Drug repurposing, a strategy aimed at identifying new therapeutic uses for existing medications, has also been transformed by the integration of LLMs like ChatGPT and DrugReAlign. By analyzing vast datasets encompassing clinical trial results, biochemical properties, and real-world patient outcomes, these models can efficiently pinpoint drugs with latent potential against diseases beyond their original indications. This capability promises to shorten drug development timelines dramatically and reduce associated costs, providing faster relief for patients in need of urgently deployable therapies.

Preclinical research, historically one of the most labor-intensive phases of drug development, benefits immensely from LLM-powered predictive analytics. Advanced models including GPT-4, CancerGPT, and LEDAP exhibit exceptional proficiency in simulating and forecasting a compound’s pharmacokinetic properties, toxicity profiles, and drug-drug interactions. Through in silico experimentation, these tools enhance the accuracy and scope of preclinical assessments, allowing researchers to anticipate adverse effects before costly and time-consuming lab tests or animal studies. The integration of these models accelerates safety evaluation and informs rational decision-making at critical junctures.

Clinical trials, the final and most complex stage in drug development, present enormous data handling challenges due to their scale and regulatory scrutiny. LLMs such as SEETrial have been developed to support clinical decision-making by extracting and synthesizing relevant data from electronic health records, trial protocols, and outcome measurements. Their ability to detect subtle patterns and correlations assists in refining patient selection, monitoring safety signals in real-time, and predicting trial endpoints. The automation and enhanced insight gained through these models promise to reduce trial costs, improve patient safety, and ultimately facilitate the approval process.

Despite these breakthroughs, the deployment of LLMs in drug development is not without significant obstacles. One pressing issue is the scarcity of high-quality, comprehensive datasets essential for training and validating these models. Biomedical data often suffer from fragmentation, proprietary restrictions, and variability across populations, which impairs model generalizability. Moreover, the computational demands of training and fine-tuning large language models remain formidable, requiring substantial infrastructure investments. These factors collectively limit the widespread, democratized application of LLMs at present.

Additionally, the inherent complexity of AI decision-making and its “black-box” nature present challenges for interpretability and trust in clinical contexts. Ensuring algorithmic transparency and enabling explainability are crucial for gaining the confidence of regulatory bodies, clinicians, and patients. Ethical considerations surrounding patient privacy, data security, and bias mitigation remain central concerns as these models increasingly interact with sensitive health information. Addressing these issues will necessitate continual multidisciplinary collaboration among AI experts, pharmacologists, ethicists, and healthcare providers.

Looking forward, the researchers underscore a vision of synergistic partnerships between human expertise and artificial intelligence. Rather than viewing LLMs as replacements for human researchers, the optimal trajectory involves coalescing human intuition with AI-driven insights to tackle medicine’s most persistent challenges. Future research directions emphasize enhancing LLMs’ cross-modal learning capabilities to integrate diverse biochemical data types and experimental modalities. Moreover, developing specialized interfaces to seamlessly embed LLMs alongside biochemical analysis tools and laboratory workflows is anticipated to maximize practical utility.

Refinements in fine-tuning methodologies also represent a critical frontier. Tailoring base language models to specific subdomains of pharmacology or particular diseases can amplify accuracy and relevance. Equally important is the establishment of robust validation frameworks to rigorously assess prediction reliability, safety, and reproducibility. These efforts are fundamental not only to advancing scientific understanding but also to fulfilling regulatory requirements that ensure patient protection.

In sum, the infusion of large language models into drug development constitutes a paradigm shift with vast implications. Their capacity to decode intricate biological languages, generate innovative molecular designs, and streamline clinical evaluations promises to accelerate the delivery of effective therapies. While challenges persist, the convergence of AI advancements and pharmaceutical science heralds a new era of collaborative intelligence where machine learning augments human ingenuity in the pursuit of improved global health outcomes. As Dr. Peng Luo eloquently concludes, fostering this alliance between humans and LLMs will pave the way for transformative breakthroughs in medicine.

Subject of Research: Not applicable
Article Title: Applications of Large Language Models in Drug Development
News Publication Date: Not specified
Web References: http://dx.doi.org/10.1016/j.cmp.2025.06.003
References: Not specified
Image Credits: Anqi Lin, Xiuhui Fang, Aimin Jiang, Chang Qi, Wenyi Gan, Lingxuan Zhu, Weiming Mou, Dongqiang Zeng, Mingjia Xiao, Guangdi Chu, Shengkun Peng, Hank Z.H. Wong, Lin Zhang, Hengguo Zhang, Xinpei Deng, Quan Cheng, Haoran Zhang, Zhuocheng Zhong, Zhengrui Li, Bufu Tang, and Peng Luo
Keywords: Health and medicine